Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
RNA Editing02:23

RNA Editing

RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2018
Same author

Heterogeneity in the properties of mutant secreted lymphocyte antigen 6/urokinase receptor-related protein 1 (SLURP1) in Mal de Meleda.

The British journal of dermatology·2015
Same author

Stable isotope imaging of biological samples with high resolution secondary ion mass spectrometry and complementary techniques.

Methods (San Diego, Calif.)·2014
Same author

Free fatty acids are associated with metabolic syndrome and insulin resistance but not inflammation in systemic lupus erythematosus.

Lupus·2012
Same author

Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 and the intravascular processing of triglyceride-rich lipoproteins.

Journal of internal medicine·2012
Same author

Evaluation of macrophage-specific promoters using lentiviral delivery in mice.

Gene therapy·2011
Same journal

Inflammation as a Fulcrum in Cardiovascular Disease: The Evolving Case for High-Sensitivity C-Reactive Protein.

Trends in cardiovascular medicine·2026
Same journal

Comment on "advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation".

Trends in cardiovascular medicine·2026
Same journal

Response to: Comment on "Advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation" (TCM-D-26-00198).

Trends in cardiovascular medicine·2026
Same journal

High-sensitivity C-reactive protein as a prognostic biomarker in cardiovascular diseases: implications for atherosclerosis, chronic kidney disease, and heart failure - a review.

Trends in cardiovascular medicine·2026
Same journal

The cost of false dichotomies in a dynamic disease.

Trends in cardiovascular medicine·2026
Same journal

Late-presenting ST-segment elevation myocardial infarction: is it just a matter of time? From temporal cutoffs to biological staging.

Trends in cardiovascular medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes
08:35

Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes

Published on: July 17, 2021

Genetic abnormalities in apolipoprotein B.

S G Young1, M F Linton

  • 1Gladstone Foundation Laboratories for Cardiovascular Disease, Cardiovascular Research Institute. Department of Medicine, University of California, San Francisco, CA 94140-0608, USA.

Trends in Cardiovascular Medicine
|January 18, 2011
PubMed
Summary
This summary is machine-generated.

Mutations in the apolipoprotein B (apo-B) gene significantly impact blood cholesterol. Specific apo-B gene mutations can lead to either low or high cholesterol levels by affecting protein production or receptor binding.

More Related Videos

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Related Experiment Videos

Last Updated: Jun 5, 2026

Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes
08:35

Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes

Published on: July 17, 2021

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Area of Science:

  • Genetics
  • Biochemistry
  • Cardiovascular Science

Background:

  • Apolipoprotein B (apo-B) is crucial for lipoprotein metabolism and cholesterol transport.
  • Genetic variations in the apo-B gene are known to influence plasma lipid levels.
  • Understanding apo-B gene mutations is key to deciphering cholesterol level variations.

Purpose of the Study:

  • To analyze the impact of different apolipoprotein B (apo-B) gene mutations on blood cholesterol levels.
  • To elucidate the relationship between apo-B gene structure, function, and resulting lipoprotein metabolism.
  • To understand the genetic basis for variations in cholesterol levels within the population.

Main Methods:

  • Review and analysis of existing studies on apolipoprotein B (apo-B) gene mutations.
  • Categorization of mutations based on their effect on apo-B protein translation and function.
  • Correlation of specific mutation types with observed blood cholesterol phenotypes (low or high).

Main Results:

  • Mutations preventing full-length apo-B translation lead to low blood cholesterol.
  • A specific missense mutation impairs low-density lipoprotein receptor binding, causing slow clearance and high cholesterol.
  • These findings highlight the diverse roles of apo-B in cholesterol homeostasis.

Conclusions:

  • Apolipoprotein B (apo-B) gene mutations are a significant determinant of blood cholesterol levels.
  • Different types of apo-B mutations result in distinct alterations in cholesterol metabolism.
  • Studying apo-B gene variations enhances our knowledge of lipoprotein structure-function relationships and cholesterol regulation.